Physician profile
Barbara M Michael
NPI 1962616789
$2,035.61
in general payments reported to CMS, 2019-2025
29 companies · $790 in 2025
The $790 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.95 · 2022: $24.39 · 2023: $372 · 2024: $835 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $385.52 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $306.98 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $148.24 | 2023-2025 | Rexulti |
| Dynavax Technologies Corporation | $122.48 | 2023-2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.53 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $92.38 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $83.96 | 2024-2025 | Airsupra |
| Abbott Laboratories | $73.04 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $67.06 | 2025 | |
| Organogenesis INC. | $54.90 | 2025 | Apligraf |
| Dexcom, INC. | $54.81 | 2023-2024 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $52.53 | 2024-2025 | Apretude |
| Corcept Therapeutics | $51.61 | 2024 | Korlym |
| Abiomed | $46.80 | 2025 | |
| Irhythm Technologies, INC. | $43.97 | 2024 | Zio Monitor, Zio Xt Patch |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $40.33 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $38.87 | 2023-2024 | Shingrix |
| Organon LLC | $38.34 | 2021-2022 | |
| C2n Diagnostics, LLC | $37.10 | 2025 | Precivityad2 |
| Mylan Specialty L.P. | $32.66 | 2024 | Yupelri |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.20 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $24.01 | 2024 | Injectafer |
| Antares Pharma, INC. | $22.84 | 2025 | Xyosted |
| Hologic Sales and Service, LLC | $19.57 | 2025 | Aptima, Thinprep 2000 Processor |
| Phathom Pharmaceuticals, INC. | $18.65 | 2025 | Voquezna |
| Amgen INC. | $16.01 | 2025 | Evenity |
| Edwards Lifesciences Corporation | $14.75 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Xeris Pharmaceuticals, INC. | $14.45 | 2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $13.02 | 2023 | Proquad, M-M-R II, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.